Amarin Corp Plc (AMRN)

[dukesking]

RSM, I understand the concern and frustration over scripts growth. My view is that scripts will grow slowly going forward, due to recent favorable changes in formularies, continued awareness development amongst KOL’s-medical societies-insurers-PBM’s-HMO’s-doctors-patients. Additionally, the fact that more people are returning to doctors, getting tests and looking for additional ways to protect themselves from CVD events and CV-19 and it’s mutations. The recent court decisions should have a positive effect on scripts going forward. These events should start to show an impact over the next 6-12 months. More rapidly if P1&2 show significant beneficial results. More work needs to be done to promote more patient/doctor conversations for Vascepa and increasing access and lowering the cost to the consumer. In other words, I believe we reached the bottom and it’s going to be a slow and steady climb from here.